Table 3.
Effect of SVPII on M-NFS-60 cell cycle progression (96 h; % of total cells)
| Group | G0-G1 | G2-M | S |
|---|---|---|---|
| 96 h Control |
45.51 ± 13.52 |
8.51 ± 2.95 |
41.97 ± 16.47 |
| Serum-free control |
71.56 ± 5.60 |
8.16 ± 5.10 |
20.29 ± 10.71 |
| SVPII 3 mg/L |
41.22 ± 14.96 * |
4.29 ± 2.70 |
54.47 ± 17.66 * |
| IL-3 10 μg/L | 51.81 ± 18.23 | 3.11 ± 1.40 | 44.88 ± 19.87 |
Cells were incubated in media containing 10% FCS + 62 μg/L rhM-CSF for 96 h (96 h control). All other cultures were treated with media plus rhM-CSF but without serum for 24 h and then treated for an additional 72 h with media supplemented with 10% FCS + 62 μg/L rhM-CSF (serum-free control) or treated with SVPII 3 mg/L or IL-3 10 μg/L in the same media. * P < 0.05 vs. serum-free control.